Teclistamab has received accelerated approval from the European Medicines Agency (EMA) for the treatment of adult patients who have received ≥3 prior therapies including an immunomodulatory agent, a proteasome inhibitor (PI), and an anti-CD38 antibody [5], and has received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed/refractory MM (RRMM), who have received ≥4 prior therapy lines [6]. Here, CD38 is linked to Miyoshi myopathy.